Vascular endothelial growth factor gene therapy - Valentis

Drug Profile

Vascular endothelial growth factor gene therapy - Valentis

Alternative Names: VEGF-165 gene therapy - Valentis

Latest Information Update: 27 Sep 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valentis
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 27 Sep 2006 No development reported - Phase-II for Ischaemic heart disorders in Finland (Intracoronary)
  • 27 Sep 2006 No development reported - Phase-II for Peripheral vascular disorders in Finland (IV)
  • 14 Jul 2003 A study has been added to the Ischaemic heart disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top